Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated March 10, 2025, reports on the headline results of the REDEFINE 2 phase 3 clinical trial. The trial evaluates CagriSema, a fixed-dose combination of cagrilintide and semaglutide, for the treatment of adults with obesity or overweight and type 2 diabetes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical trial announcement and does not contain financial statement data.
Material Changes and Clinical Results
The REDEFINE 2 trial achieved its primary endpoint, demonstrating statistically significant and superior weight loss with CagriSema compared to placebo over 68 weeks.
- Weight Loss (Trial Product Estimand): CagriSema achieved 15.7% weight loss versus 3.1% with placebo.
- Weight Loss (Treatment Policy Estimand): CagriSema achieved 13.7% weight loss versus 3.4% with placebo.
- Co-Primary Endpoint: 89.7% of CagriSema patients achieved 5% or more weight loss, compared to 30.3% of placebo patients.
- Study Population: 1,206 randomized patients with a mean baseline body weight of 102 kg.
- Dosing: 61.9% of patients on CagriSema were on the highest dose after 68 weeks.
Guidance, Outlook, and Risks
Regulatory Outlook: Novo Nordisk expects to file for the first regulatory approval of CagriSema in the first quarter of 2026. Detailed results from REDEFINE 1 and REDEFINE 2 are scheduled for presentation at a scientific conference in 2025.
Safety Profile: CagriSema demonstrated a safe and well-tolerated profile. The most common adverse events were gastrointestinal, mostly mild to moderate, and diminished over time, consistent with the GLP-1 receptor agonist class.
Management Commentary: Martin Holst Lange, Executive Vice President for Development, stated that the results confirmed the superior efficacy of CagriSema in the target population and expressed intent to bring the therapy to regulatory authorities for millions of patients in need.
Key Facts for Investor Verification
- Verify the timeline for the first regulatory filing of CagriSema (Q1 2026).
- Monitor the upcoming scientific conference presentation for detailed data on REDEFINE 1 and REDEFINE 2.
- Assess the competitive landscape, specifically the REDEFINE 4 trial comparing CagriSema to tirzepatide.
- Review the safety data regarding gastrointestinal adverse events in the full clinical report.